Deals & Corporate Governance

  • December 17, 2024

    Sandoz Cuts $275M Deal For More Price-Fixing Claims

    Swiss drugmaker Sandoz said Tuesday it has reached a $275 million settlement to end claims from consumers, insurers and others in the sprawling multidistrict litigation over alleged price-fixing in the generic-drug industry.

  • December 17, 2024

    Bigger, Mature Deals May Define 2025 Healthcare Landscape

    As the healthcare industry returns to normalcy after the peak of the pandemic, look for a repeat of some pre-2020 deal trends.

  • December 16, 2024

    Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement

    Investors in biotech company Ginkgo Bioworks Holdings Inc. have gotten final approval for their $17.75 million deal to end proposed class action claims that the company and its leaders distorted Ginkgo's finances, mischaracterizing certain related party deals, to garner shareholder support for its merger with a special purpose acquisition company.

  • December 16, 2024

    Merger Enforcers End Year On Upswing

    The Biden administration's antitrust enforcers have boasted that one side effect of their aggressive approach to merger enforcement has been helping stop problematic deals from being cut in the first place, but the agencies also scored key court rulings blocking transactions in their final year that could have a more enduring effect.

  • December 16, 2024

    Becton Dickinson To Pay SEC $175M Over Pump Claims

    Becton Dickinson & Co. has agreed to pay $175 million to settle the U.S. Securities and Exchange Commission's allegations that the medical device manufacturer misled investors about the risks of selling its Alaris infusion pump and overstated its income, the agency announced Monday.

  • December 13, 2024

    Pharma Co. Brass Face Investor Suit Over Drug Trial Probe

    Officers and directors of cancer treatment developer MacroGenics Inc. have been hit with a shareholder derivative action alleging they breached their fiduciary duties after the company announced three study participant deaths were being probed for a potential connection to the company's therapies.

  • December 13, 2024

    What's Left In $400M Skinny Label Row? A Lot, Court Says

    A number of key issues remain live in the $400 million fight between Teva Pharmaceuticals and GlaxoSmithKline over whether the generic-drug maker induced healthcare providers to infringe the brand-name company's heart drug patent, including the availability of a new trial, a Delaware federal judge has said.

  • December 13, 2024

    Taxation With Representation: Kirkland, Davis Polk, Wachtell

    In this week's Taxation With Representation, Google and TPG Rise Climate partner with Intersect Power, Gen Digital Inc. acquires MoneyLion Inc., Patient Square Capital acquires Patterson Companies Inc., and the Buffalo Bills and Miami Dolphins sell minority ownership shares to private equity firms.

  • December 12, 2024

    Medicare Could Lose Billions From 'Patent Abuse,' Group Says

    The $6 billion a year Medicare is supposed to save by negotiating drug prices under the Inflation Reduction Act is close to the billions of dollars the government could lose due to "patent abuse" by drugmakers, according to a new report by a consumer interest group.

  • December 11, 2024

    AADI Enlists NY Court To Enforce Cancer Drug Award

    California-based AADI Bioscience Inc. is asking a New York federal court to enforce an arbitral award rejecting a more than $15 million claim asserted by a Hong Kong biopharmaceutical company following a dispute over a deal to market a new cancer drug in China.

  • December 11, 2024

    Kirkland-Led Patient Square Pays $4.1B For Animal Health Co.

    Healthcare-focused private equity firm Patient Square Capital on Wednesday unveiled plans to acquire and take private dental and animal health distributor Patterson Companies Inc. in a $4.1 billion deal built by several law firms.

  • December 10, 2024

    Bristol-Myers Said To Renege On $450M Milestone Promise

    Former security holders of a biotechnology company Bristol-Myers Squibb acquired in 2016 hauled the pharmaceutical giant into Delaware's Court of Chancery on Monday, accusing it of using "patent prosecution sleight of hand" to avoid paying up to $450 million in promised milestone payments related to an autoimmune disorder treatment.

  • December 10, 2024

    Judge Won't Cull EpiPen Antitrust Action Against Mylan

    Mylan Pharmaceuticals didn't get the early exit it sought from litigation accusing it of working with Pfizer to inflate the price of the latter's popular auto-injecting emergency allergy medication EpiPen, as a Kansas federal judge has ruled the case must move on to discovery.

  • December 10, 2024

    Mandarin-Speaking Attys In Demand Amid China Biotech Push

    Amid a shift in licensing deals between Chinese and U.S. biotech companies, Mandarin-speaking attorneys with deep experience in the healthcare space are garnering new attention.

  • December 09, 2024

    3rd Circ. Affirms NLRB's COVID-19 Bonus Pay Order

    The Third Circuit upheld on Monday a National Labor Relations Board decision finding a New Jersey nursing home illegally cut or stopped COVID-19 bonuses for unionized workers, supporting the board's assertion that the bonuses were hazard pay that the company was required to negotiate with the union.

  • December 09, 2024

    NC Attorney General Cans Counterclaims In HCA Hospital Suit

    North Carolina Attorney General Josh Stein has immunity from counterclaims brought by HCA Healthcare in an enforcement suit centered on the for-profit health network's actions since purchasing an Asheville hospital five years ago, a state Business Court judge has ruled.

  • December 06, 2024

    Taxation With Representation: Skadden, Gibson Dunn

    In this week's Taxation With Representation, BlackRock buys HPS Investment Partners, TreeHouse Foods Inc. buys Harris Tea, Aya Healthcare acquires Cross Country Healthcare, and Bruin Capital launches a soccer representation business.

  • December 05, 2024

    Providers' $2.8B BCBS Antitrust Deal Gets Judge's Initial OK

    An Alabama federal judge has given his initial approval for a $2.8 billion settlement inked between Blue Cross Blue Shield Association and a proposed class of medical providers in a more than 12-year-old antitrust case targeting association rules.

  • December 06, 2024

    FINRA Fines Firm $900K Over SPAC Underwriting Fee Issues

    The Financial Industry Regulatory Authority has fined New York-based LifeSci Capital LLC nearly $1 million over claims that it received and failed to disclose unfair and unreasonable fees for an initial public offering it underwrote.

  • December 04, 2024

    Withers IP Partners Hop To Sullivan & Worcester

    Sullivan & Worcester LLP has said the Boston firm picked up a team of five intellectual property lawyers, including two partners, from Withers who have expertise in filing patents and working on deals for biotech startups. 

  • December 04, 2024

    Aya Healthcare Buys Fla. Peer Cross Country In $615M Deal

    Talent software and staffing company Aya Healthcare, steered by Procopio, will acquire Davis Polk & Wardwell-guided Cross Country Healthcare in an $18.61-per-share cash transaction worth roughly $615 million that will take the company private, according to a Wednesday statement.

  • December 04, 2024

    Fed. Circ. Judge Condemns 'Nonsense' Law In Antibody Fight

    U.S. Circuit Judge Todd Hughes called the Federal Circuit's case law on interpreting preambles in patent claims "nonsense" on Wednesday, expressing frustration as a panel tried to work through whether Xencor Inc.'s antibody patent application was too broad.

  • December 03, 2024

    US Claims Court Backs HHS Agency's $20.5M IT Deal Choice

    A federal claims court judge has denied a protest of a $20.5 million U.S. Department of Health and Human Services information technology deal, saying an HHS agency reasonably concluded that it had only "some confidence" in a government contractor protester.

  • December 03, 2024

    SEC Says Biopharma's Cooperation Helped It Avoid Penalty

    A Houston biopharmaceutical company accused of misleading investors about the regulatory status of two cancer drugs agreed to settle the U.S. Securities and Exchange Commission's action against it on Tuesday without paying a dime, in recognition of what the SEC said was the company's self-reporting and cooperation with investigators.

  • December 03, 2024

    9th Circ. Ponders AIDS Generic Drug Reimbursement

    A Ninth Circuit panel heard arguments Tuesday on a Seattle pharmacy's dispute with a benefits manager over reimbursements for the generic version of the HIV/AIDS drug Truvada, with one judge asking if the pharmacy was stuck with a lopsided deal, but also questioning if the contract obligated the payments.

Expert Analysis

  • Preparing For Legal Scrutiny Of Data Retention Policies

    Author Photo

    Two recent cases involving Google and Meta should serve as a call to action for companies to ensure their data retention policies are updated and properly implemented to the degree of being able to withstand judicial scrutiny, especially as more data is generated by emerging technologies, say Jack Kallus and Labeed Choudhry at Kaufman Dolowich.

  • Congress Must Reform PBMs To Lower The Cost Of Insulin

    Author Photo

    When the U.S. Senate Committee on Health, Education, Labor and Pensions meets Wednesday to ask why insulin prices are increasing, they should follow the money, and work on curtailing the practices of pharmacy benefit managers that inflate drug prices, says David Balto, a former policy director at the Federal Trade Commission.

  • Attorneys Should Have An Ethical Duty To Advance DEI

    Author Photo

    National and state bar associations are encouraging attorneys to apply diversity, equity and inclusion practices in the legal profession and beyond, and these associations should take it one step further by formally recognizing ethical duties for attorneys to promote DEI, which could better the legal profession and society, says Elena Mitchell at Moore & Van Allen.

  • Data-Driven Insights Are Key To Attracting Today's Clients

    Author Photo

    As law firm growth slows and competition for clients increases, modern firms must rely on robust data analytics to develop the sector-based expertise and industry insights that clients increasingly prioritize in relationships with counsel, says Lavinia Calvert at Intapp.

  • Ghosting In BigLaw: Why Better Feedback Habits Are Needed

    Author Photo

    Not giving assignments or constructive criticism to junior associates can significantly affect their performance and hours, potentially leading them to leave the firm, but partners can prevent this by asking the right questions and creating a culture of feedback, says Rachel Patterson at Orrick.

  • Law Needs A Balance Between Humanism And Formalism

    Author Photo

    A recent Law360 guest article rightly questions the pretextual pseudo-originalism that permits ideology to masquerade as judicial philosophy, but the cure would kill the patient because directness, simplicity and humanness are achievable without renouncing form or sacrificing stare decisis, says Vanessa Kubota at the Arizona Court of Appeals.

  • FTC's Criminal Liaison Unit Enhances Merger Risks

    Author Photo

    As it enters its second year, the Criminal Liaison Unit within the Federal Trade Commission’s Bureau of Competition may streamline and sharpen efforts to detect and refer substantive and procedural violations to prosecutors, increasing the chances of a merger review uncovering potential criminal activity, say attorneys at Norton Rose.

  • Short Message Data Challenges In E-Discovery

    Author Photo

    As short message platforms increasingly dominate work environments, lawyers face multiple programs, different communication styles and emoji in e-discovery, so they must consider new strategies to adapt their processes, says Cristin Traylor at Relativity.

  • Thomas Report Is Final Straw — High Court Needs Ethics Code

    Author Photo

    As a recent report on Justice Clarence Thomas' ongoing conflicts of interest makes evident, Supreme Court justices should be subject to an enforceable and binding code of ethics — like all other federal judges — to maintain the credibility of the institution, says Erica Salmon Byrne at Ethisphere.

  • Joint Representation Ethics Lessons From Ga. Electors Case

    Author Photo

    The Fulton County district attorney's recent motion to disqualify an attorney from representing her elector clients, claiming a nonconsentable conflict of interest, raises key questions about representing multiple clients related to the same conduct and highlights potential pitfalls, say Hilary Gerzhoy and Grace Wynn at HWG.

  • Lawyer Discernment Is Critical In The World Of AI

    Author Photo

    In light of growing practical concerns about risks and challenges posed by artificial intelligence, lawyers' experience with the skill of discernment will position them to help address new ethical and moral dilemmas and ensure that AI is developed and deployed in a way that benefits society as a whole, says Jennifer Gibbs at Zelle.

  • Cannabis Considerations In Debt Collection, Credit Reporting

    Author Photo

    While companies that collect debts arising from cannabis purchases, and consumer reporting agencies that furnish information concerning such debts, may not be governed by consumer protection laws, they should probably act like it by implementing compliance programs that heed state and federal requirements, say Corey Scher and Joshua Horn at Fox Rothschild.

  • Don't Forget Alumni Engagement When Merging Law Firms

    Author Photo

    Neglecting law firm alumni programs after a merger can sever the deep connections attorneys have with their former firms, but by combining good data management and creating new opportunities to reconnect, firms can make every member in their expanded network of colleagues feel valued, say Clare Roath and Erin Warner at Troutman Pepper.